戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ffect is not associated with regression of a keratoacanthoma.
2 associated with squamous cell carcinomas and keratoacanthomas.
3 ell carcinoma (65 [19%] of 337 patients) and keratoacanthomas (34 [10%]), rash (30 [9%]), and abnorma
4 benign and malignant human tumors, including keratoacanthoma and squamous cell carcinoma.
5 in high-fat-fed mice decreased the number of keratoacanthomas and squamous cell carcinomas per mouse
6 ession of EJras was detectable in all of the keratoacanthomas and squamous cell carcinomas.
7 ene in both the initiation and regression of keratoacanthoma, and in the development of squamous cell
8 cerous epidermis away from tumors, by 68% in keratoacanthomas, and by 224% in squamous cell carcinoma
9 idermal tumors such as verrucous papillomas, keratoacanthomas, and squamous cell carcinomas (SCC).
10 eaction, hair changes, verrucous papillomas, keratoacanthomas, and squamous cell carcinomas.
11       Cutaneous squamous-cell carcinomas and keratoacanthomas are common findings in patients treated
12                                  Benign skin keratoacanthomas arose and often regressed in treated tr
13 cutaneous squamous cell carcinomas (cSCC) or keratoacanthomas as a side effect in 18% to 30% of patie
14 e F1 transgenic progenies developed multiple keratoacanthomas at about 3 days after birth.
15 ficient mice are predisposed to formation of keratoacanthomas, cutaneous tumors thought to originate
16 describe an original mouse model of invasive keratoacanthoma driven by skin-specific expression of th
17 inically, we found that human differentiated keratoacanthomas expressed low levels of uPAR and high l
18 unding induces benign tumors (papillomas and keratoacanthomas) in InvEE mice.
19 xpression is reduced in both mouse and human keratoacanthomas, indicating tumor-suppressive propertie
20                                              Keratoacanthoma (KA) is a common keratinocyte neoplasm t
21                                              Keratoacanthoma (KA) is a variant of cutaneous squamous
22 nd invasive squamous-cell carcinomas (SCCs), keratoacanthoma (KA), and normal skin samples from both
23 ntaneously self-regressing tumour, cutaneous keratoacanthoma (KAs), to identify physiological mechani
24 mas with BRAF V600E mutations but may induce keratoacanthomas (KAs) and cutaneous squamous cell carci
25 re have been no previous reports of eruptive keratoacanthomas (KAs) in patients receiving pembrolizum
26 possibly accounting for up to 60% of cSCC or keratoacanthoma lesions with RAS mutations, but other co
27 ed pinguecula (n = 1, 13%), and scleritis vs keratoacanthoma (n = 1, 13%).
28        Cutaneous squamous-cell carcinoma and keratoacanthoma occurred in 1% of patients in the combin
29 ib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensiti
30 which clinically and histologically resemble keratoacanthomas or well-differentiated squamous cell ca
31                  Grade 3 toxicities included keratoacanthomas, rash, fatigue, and arthralgia.
32 usly regressed in about 2 months, similar to keratoacanthoma regression in humans.
33 nt in cutaneous squamous-cell carcinomas and keratoacanthomas that develop in patients treated with v
34 situ and adult mice developed papillomas and keratoacanthomas, the latter having a high frequency of
35 uamous cell carcinomas (well-differentiated, keratoacanthoma type) at uninvolved sites including the
36 eous squamous-cell carcinomas (the majority, keratoacanthoma type) were diagnosed in 26% of patients.
37 se mice exhibited impaired NER and developed keratoacanthomas upon chronic UVB exposure.
38  a relatively poor prognosis; in contrast, a keratoacanthoma, which eventually regresses, does not me